Current stage in inflammatory bowel disease: What is next?

Table 3 Genetic association studies of infliximab response in inflammatory bowel disease patients

Study (year)	Patients recruited	Response criteria	Genes investigated	Conclusion
Taylor et al[55] (2001)	75	CDAI	Polymorphims TNF/LTA region	Homozygosity for the LTA1-1-1-1 haplotype may identify subgroups with poorer response
Louis et al[56] (2002)	226	CDAI	TNFA	No association with treatment outcome
Mascheretti et al[57] (2002)	90	CDAI	TNF and TNFR polymorphism	196Arg homozygotes had poorer clinical response than 196Met
	444			heterozygotes and homozygotes (P = 0.036)
				No predictive treatment outcome
Mascheretti et al[58] (2002)	534	CDAI	CARD15/NOD2	A strong relation to susceptibility to CD but not association with treatment outcome
Vermeire et al[59] (2002)	245	CDAI	CARD15/NOD2	Not predictive of treatment outcome
Pierik et al[60] (2004)	166	CDAI	TNF/TNFR	Biological response to infliximab was lower in patients carrying TNFR1-36G
Matsukura et al[61] (2008)			TNFRSF1A	28% of G allele heterozygotes and homozygotes responded
	80	HBI	TNFRSF1B	compared to 73% of A allele homozygotes (P = 0.04)
				5% of patients with AT haplotype responded compared to 20%-40% of patients with other haplotypes (P = 0.01)
Louis et al[62] (2004)	200	CDAI	FcγRIIIa	Positive (V/V genotype) association with good treatment outcome
Urcelay et al[63] (2005)	40	CDAI	IBD5(5q31)	Polymorphims TT is associated with negative response
Hlavaty et al[64] (2005)	287	CDAI	FASL/CASP9	Positive association
Hlavaty et al[65] (2007)	287	CDAI	FASL	Negative association (stadistical model)
Willot et al[66] (2006)	189	CRP	CRP	Polymorphims evaluated are not associated with treatment outcome
Dideberg et al[67] (2006)	214	CDAI	TNF/LTA region	No association
Dideberg et al[68] (2006)	186	CDAI and CRP	ADAM17	Minor allele homozygotes for each SNP associated with clinicalresponse (P < 0.002)
Jürgens et al[69] (2010)	90	CAI	IL-23RIL-2/IL-21	Homozygous carriers of IBDrisk-increasing IL-23R variants more likely to respond to infliximab than homozygous carriers of IBD risk-decreasing IL-23R variants (P = 0.001)
Dubinsky et al[70] (2010)	94	HBI and Partial Mayo score	rs2241880 2q37/ATG16L1rs21889625q31rs6908425 6p22/CDKAL1rs762421 21q22/ICOSLGrs2395185 6p21/HLA-DAQ1rs2836878 21q22/BRWD1	Six known susceptibility lociassociated with primary nonresponse(P < 0.05). Only the 21q22.2/BRWDIloci remained significant in thepredictive model

Aailable from: URL: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4419078/.